MB-110
Phase 1Small molecule
MB-110 is one of 42 small molecule programs targeting Hepatitis C. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
306 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Zepatier
Merck & Co.Phase 3
Peginterferon Alfa-2
RochePhase 3
Lexapro
AbbViePhase 3
Victrelis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Pegylated Interferon
Merck & Co.Phase 3
TMC435
Johnson & JohnsonPhase 3
Zetia
OOrganon and Co
Phase 3
Peg-Interferon Alfa-2a
Bristol-Myers SquibbPhase 3
Ombitasvir/paritaprevir/ritonavir
AbbViePhase 3
Thymalfasin
SSciClone Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MB-110. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMicrobio Co Ltd